Anthos Therapeutics News and Activities

Anthos Therapeutics is owned by Novartis.

Novartis is one of the...

• Forbes Global 2000 (#100);
• Fortune 500 Europe (#62);
• Global Fortune 500 (#287);
• Stoxx 600;
• Swiss market index;
• TOB Iconic 10,000.

Novartis is a company listed under the stock ticker NOVN (CH).

Novartis has a direct presence in 35 countries.

Novartis has 54 subsidiaries including Alcon, Alcon ANZ and Alcon APAC.

They are in:

• Pharmaceuticals78%
• Medical Equipment11%
• Other11%

Acquisition, funding and merger involving Novartis.

• Novartis has acquired Avidity Biosciences (posted on March 3 2026).
• Novartis has announced the acquisition of Avidity Biosciences  (posted on October 27 2025).
• Novartis has announced the acquisition of Tourmaline Bio  (posted on September 9 2025).

View the org chart displaying its 5 main executives

Most searched biographies at Anthos Therapeutics

• Mike Doremus, Head of Technical Operations
• Mia Kelley, General Counsel
• Dan Bloomfield, Chief Medical Officer

Popular executive movements at Anthos Therapeutics

• Erika Dahl, Program Manager, has left the company  (posted on November 18 2025).
• Gi Gi Galiano, Vice President, Program & Risk Management and Human Resources Operations, has left the company  (posted on November 17 2025).

Popular executive movements at Novartis

• Liz Moran has joined the company as Vice President, Talent and Development  (posted on May 31 2026).
• Mukul Mehta, who was Head of Business and Digital Finance and Tax, is promoted to Chief Financial Officer  (posted on March 18 2026).
• Charles Swanton has joined the company as Director  (posted on March 13 2026).

Click here to view some more movements at Novartis

Create your alert
to follow the executive moves at Anthos Therapeutics.

Novartis has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Anthos Therapeutics

• Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront - Anthos Therapeutics
• Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
• Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
• Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion  - Anthos Therapeutics
• Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with At
• Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban - Anthos Therapeutics
• Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer - Anthos Therapeutics
• Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer - Anthos Therapeutics
• New anti-clotting medication reduces bleeding among people with atrial fibrillation
• New anti-clotting medication found to reduce bleeding among people with atrial fibrillation
• View more press releases Close

Social media about Anthos Therapeutics

• Anthos Therapeutics on Wikipedia, Google News & Yahoo Finance
• Anthos Therapeutics on LinkedIn, X (Twitter) & YouTube